In 2024, the pancreatic cancer precision medicine market globally was valued at USD 656.8 million, and it is expected to increase to USD 1.88 billion by 2030, reflecting a compound annual growth rate (CAGR) of 19.2% over the period from 2025 to 2030. Key factors fueling this growth include rising adoption of targeted therapies and immunotherapies, which are improving survival outcomes and reducing adverse effects.

Key Market Trends & Insights

• In 2024, North America led the global market, holding approximately 42.9% of revenue share.
• The Asia Pacific region is projected to post the fastest growth rate over the forecast period, with a CAGR of 6.1%.
• Among therapeutic approaches, targeted therapy claimed the largest segment share in 2024, accounting for 56.0% of the market.
• For diagnostic technologies, genomic testing dominated in 2024, with a share of 40.8%.

Detailed drivers behind these trends include: advanced diagnostic tools such as molecular profiling and liquid biopsies improving early detection; incorporation of next-generation sequencing and bioinformatics to discover new therapeutic targets; rising investments by pharmaceutical companies, academia, and governments; increasing incidence of pancreatic cancer due to lifestyle factors and an aging population; supportive regulatory environments; and collaborations across firms and institutions to speed development and commercialization of precision medicine for pancreatic cancer.

Market Size & Forecast

• Market size in 2024: USD 656.8 million
• Projected market size by 2030: USD 1.88 billion
• CAGR from 2025 to 2030: 19.2%

Regional dynamics show North America as the largest market in 2024, with Asia Pacific as the region with fastest expected growth. Developments in diagnostic capability (e.g. non-invasive tests) and therapeutic innovation (combining chemotherapy with precision medicine, targeted drug discovery) are expected to continue to drive the market forward.

Order a free sample PDF of the Pancreatic Cancer Precision Medicine Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insight

Major players in this market are involved in development of targeted therapies, immunotherapies, diagnostics including companion diagnostics, and diagnostic technology innovations such as liquid biopsy and genomic testing. Examples of strategic methods include partnerships between diagnostics firms and pharmaceutical companies, investment in early-stage research, and regulatory initiatives supporting access to novel precision treatments.

Some of the leading companies in the pancreatic cancer precision medicine field are:

• AstraZeneca
• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Hoffmann-La Roche Ltd
• Bayer AG
• Eli Lilly and Company
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd
• PharmaCyte Biotech, Inc.
• Genentech, Inc.
• Guardant Health
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Foundation Medicine, Inc.

These companies together hold substantial share in therapy development, diagnostic tools, and clinical trial innovation. Their combined efforts influence market direction, especially in precision diagnostics, advanced therapeutics, and companion diagnostics.

Conclusion

Overall, the pancreatic cancer precision medicine market is on a strong upward trajectory from 2025 through 2030, driven by technological advances in diagnostics, strong therapeutic innovation, and increasing incidence of pancreatic cancer. Targeted therapy and genomic testing are currently the dominant segments, while chemotherapy-precision therapy combinations and liquid biopsy diagnostics are expected to grow more rapidly. With North America already leading, Asia Pacific is poised for fastest expansion. Collaboration among companies and regulatory support will continue shaping access and development of personalized treatments in this field.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.